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ABSTRACT - Signal transduction pathways essential for the survival and viability of the cell and that 
frequently present aberrant expression or function in tumors are attractive targets for pharmacological 
intervention in human cancers. In this short review we will describe the regulation exerted by the calcium-
receptor protein calmodulin (CaM) on signaling routes involving the family of ErbB receptors - highlighting 
the epidermal growth factor receptor (EGFR/ErbB1) and ErbB2 - and the adaptor protein Grb7, a 
downstream signaling component of these receptors. The signaling mechanism of the ErbB/Grb7 axis and 
the regulation exerted by CaM on this pathway will be described. We will present a brief overview of the 
current efforts to inhibit the hyperactivity of ErbB receptors and Grb7 in tumors. The currently available 
information on targeting the CaM-binding site of these signaling proteins will be analyzed, and the pros and 
cons of directly targeting CaM versus the CaM-binding domain of the ErbB receptors and Grb7 as potential 
anti-cancer therapy will be discussed. 
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
The ErbB receptors form a subfamily of RTKs that 
includes four members: EGFR/ErbB1/HER1, 
ErbB2/neu/HER2, ErbB3/HER3 and ErbB4/HER4. 
These receptors present three distinct zones: an 
extracellular region with two cysteine-rich domains 
and containing the ligand-bind site; a single 
membrane-spanning segment; and an intracellular 
region composed by a JM domain that plays an 
essential role in receptor activation, the tyrosine 
kinase catalytic domain, and a C-terminal tail 
containing a set of tyrosine residues that are auto-
phosphorylated upon receptor activation (1-4). 
The ErbB receptors share an extensive family 
of polypeptide ligands that are either very 
promiscuous or have relative or absolute preference 
for specific receptor subtypes, orchestrating in this 
manner a variety of signaling events to accomplish 
differentiated cellular responses (5, 6). These 
receptors form homo- or hetero-dimers upon ligand 
binding. This process induces a series of 
conformational changes that result in the activation 
of their intrinsic tyrosine kinase followed by the 
auto(trans)-phosphorylation of tyrosine residues (1-
4). The most likely mechanism for the ligand-
dependent activation of these receptors is the 
formation of an asymmetric dimer involving the 
allosteric interaction of the proximal and terminal 
regions of two apposed tyrosine kinase domains 
(7). Although ErbB2 does not have ligand-binding 
capacity and ErbB3 presents a non-functional 
tyrosine kinase domain, they form active 
ErbB2/ErbB3 hetero-dimers (8). 
The phospho-tyrosine residues in the active 
receptors act as docking sites for adaptor proteins 
or transducing enzymes harboring SH2 or PTB 
domains, initiating in this manner complex 
networks of signaling events (2, 4, 9, 10). 
Thereafter, the ligand/receptor complexes at the 
plasma membrane are internalized in clathrin-
coated pits. The receptors are subjected to 
ubiquitination by the E3 ubiquitin-protein ligase c-
Cbl and sorted in endosomal vesicles where they 
continue generating signals. Afterwards they are 
proteolytically degraded via the lysosomal 
pathway, previous de-ubiquitination at the 
proteasome, or directly processed via this pathway. 
Alternatively, the receptors are recycled back to the 
plasma membrane (11-13). 
The ErbB receptors participate in the control of 
an extensive variety of cellular functions, most 
prominently stimulating cell proliferation, but in 
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addition they control differentiation, cell polarity, 
cell survival mechanisms, the prevention or 
induction of apoptosis, and cell motility (14-19). 
These processes are frequently altered in neoplastic 
cells leading to cancerogenesis, tumor progression 
and the development of metastasis (18). 
Grb7 is an adaptor protein that participates in 
signal transduction events initiated from many 
active RTKs located at the plasma membrane, 
including the ErbB receptors, or from cytosolic 
tyrosine kinases such as FAK. Grb7 forms part of a 
mammalian family of adaptors that also includes 
Grb10 and Grb14 (20-24). These proteins are 
phylogenetically related to the Mig10 protein from 
Caenorhabditis elegans that is involved in the 
regulation of embryonic neural cell migration (25, 
26). 
The human GRB7 gene maps at the 17q12-
q21.1 locus in the long arm of chromosome 17 and 
encodes a 532 amino acids modular protein. This 
protein harbors an N‐terminal PR domain; a central 
GM region (for Grb and Mig10) that includes a RA 
domain, a PH domain, and a BPS domain (for 
between PH and SH2); and a SH2 domain located 
in its C-terminal segment (20-24). In human tumor 
cells Grb7 is frequently co-amplified with ErbB2 
and other neighbor genes forming the ERBB2 
amplicon (24). 
Similar to other adaptor proteins, Grb7 does 
not have intrinsic enzymatic activity but plays 
important roles participating in many signaling 
pathways. Grb7 docks via its SH2 domain at 
phospho-tyrosine residues in active RTKs, FAK, 
and other phospho-proteins. Upon recruitment by 
FAK or the EphB1 receptor Grb7 is 
phosphorylated and signals to control cell 
migration processes (27, 28). In human cancers - 
including for example breast, stomach, esophagus 
and ovary - the overexpression of Grb7, its co-
amplification with ErbB2, and/or the expression of 
an aberrant truncated variant denoted Grb7V is 
known to contribute to the invasiveness and spread 
of metastatic tumor cells (29-33). 
In addition to its well-known implication in 
cell migration, Grb7 plays additional roles in 
signaling pathways controlling other important 
physiological functions. This includes the control 
of cell proliferation, as demonstrated by disrupting 
Grb7 expression with siRNA or shRNA (34-36), 
treating cells with a cell-permeable inhibitory 
peptide targeting Grb7 (37), mutating the FAK-
mediated Grb7 phosphorylation sites (34), or 
deleting the CaM binding site of Grb7 (38). On the 
other hand, Grb7 is also an RNA-binding protein 
that interacts via its PR domain with the 5’-UTR of 
mRNAs regulating translational processes with the 
intervention of netrin-1 and FAK, and participating 
as well in the storage of mRNAs in stress granules 
under a variety of environmental conditions 
unsuitable for appropriate protein translation (39, 
40). Additionally, we have demonstrated that Grb7 
participates in the control of angiogenesis in vitro 
(41), and in vivo determining the extent and 
functional performance of the tumor-associated 
vasculature using an experimental model of glioma 
and MRI (38). 
 
CALMODULIN 
 
Many Ca2+-regulated cellular functions are 
controlled by CaM, a small Ca2+-binding sensor 
protein harboring four Ca2+-binding sites that is 
ubiquitously present in all known eukaryotic cells 
and is highly conserved across vertebrate species - 
albeit CaMs from some lower eukaryotes only have 
three functional Ca2+-binding sites (42, 43). The 
transient increase in the cytosolic concentration of 
free Ca2+ induced by many agonists, including 
mitogenic growth factors, results in the progressive 
formation of the Ca2+/CaM complex at increasing 
Ca2+ levels in living cells (44). Upon Ca2+ binding 
CaM changes its conformation exposing 
hydrophobic amino acids that favor its interaction 
with more than one hundred target proteins 
modulating their activities (42, 43). The central 
helical segment of CaM appears to wrap around the 
CaM-BD of some target proteins upon Ca2+ 
binding. The number of calcium ions bound to 
CaM required for efficient interaction with distinct 
targets varies for each protein, as experimentally 
demonstrated using peptides corresponding to the 
CaM-BDs of distinct proteins (45). For example, 
only two Ca2+ bound to CaM at their high affinity 
C-terminal sites are enough to activate CaMK-II 
(46). Nevertheless, Ca2+-free CaM (apo-CaM) is 
also able to bind and regulate many target proteins 
(47). The CaM-BDs of diverse target proteins often 
correspond to an amphipathic -helix with 
positively charged and hydrophobic amino acid 
residues usually distributed at opposite sides of the 
helix, or Ca2+-independent and Ca2+-dependent IQ 
motifs (47-49). Diverse molecular mechanisms for 
recognizing distinct CaM-dependent target proteins 
by CaM have been described (50). 
 
Targeting calmodulin in cancer 
 
Inhibition of CaM has been thought to have 
potential therapeutic effects in cancer (49, 50) 
because of its suppressing action on cell 
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proliferation and/or their capacity to revert the 
multi-drug resistance tendency of many tumor cells 
(51-54). A great variety of CaM antagonists have 
been described and their mechanisms of action 
established (55-59). This includes CaM inhibitors 
isolated from plant and animal products (60). CaM 
antagonists, however, negatively affect the 
proliferation of both normal and tumor cells, and to 
complicate matters in some instances these 
compounds have been reported to be less effective 
in transformed than in normal cells because of 
alterations in some CaM-dependent pathways in 
the former (61). Thus, as CaM is essential in all 
eukaryote cells for the regulation of a myriad of 
vital cellular functions, the widespread use of CaM 
antagonists as chemotherapeutic agents against 
cancer in a clinical setting is expected to be 
problematic. 
Therefore, it could be of interest to explore 
alternative strategies, such as the potential efficacy 
of targeting the CaM-binding region(s) of selected 
CaM-binding proteins relevant for the proliferation 
of tumor cells or other essential functions for tumor 
progression and metastatic spread. In the following 
sections, we shall discuss how targeting the CaM-
dependent ErbB/Grb7 axis at the CaM-BD of ErbB 
receptors and/or Grb7 could facilitate new 
therapeutic approaches to fight cancer. 
 
ErbB RECEPTORS AND CALMODULIN 
 
The Ca2+/CaM complex controls the functionality 
of ErbB receptors - particularly the EGFR and 
ErbB2 - by a dual mechanism, either implicating 
CaM-dependent kinases that phosphorylate and 
indirectly control their activity, down-regulation, 
trafficking and fate; or by directly binding to the 
cytosolic JM region of the receptor regulating in 
this manner its ligand-dependent activation (62). 
Our group obtained the first experimental 
evidence for CaM binding to the EGFR in a Ca2+-
dependent manner in rat liver more than twenty 
years ago (63). The CaM-BD (residues 645-660) 
was subsequently located at the cytosolic JM 
region of human EGFR (64, 65) (see Figure 1a). 
Furthermore, the occurrence of CaM/EGFR 
complexes in living cells was established, and the 
possible functional implication of this interaction 
for ligand-dependent activation of the receptor was 
determined (66-71). The recent engineering of 
conditional CaM-knockout vertebrate cell lines 
(72) has been an important breakthrough to obtain 
further evidence of the positive regulatory action 
that the Ca2+/CaM complex exerts on the ligand-
dependent activation of the EGFR in living cells 
without the need to use CaM antagonists, as these 
compounds could have unwanted off-target side 
effects (73). 
The CaM-BD appears to be highly conserved 
in all ErbB receptor family members except in 
ErbB3 that lacks intrinsic tyrosine kinase activity 
(74), underscoring the relevance of this domain for 
its activation. High affinity binding of Ca2+/CaM to 
peptides corresponding to the sequences of the 
proposed CaM-BD of all the ErbB receptors has 
been determined, except for the ErbB3 peptide that 
presented lower affinity (68). In the ligand-free 
EGFR the CaM-BD appears to play an auto-
inhibitory role because of the electrostatic 
interaction of this region with the inner leaflet of 
the plasma membrane, preventing in this manner 
the ligand-independent constitutive activation of 
the receptor (68, 71). 
It has been experimentally established that 
CaM also binds to ErbB2 in a Ca2+-dependent 
manner modulating its tyrosine kinase activity, the 
downstream signaling pathways of the receptor and 
cell growth (75, 76). Nevertheless, it appears that 
Ca2+/CaM and apo-CaM interact with ErbB2, as 
CaM binds to ErbB2 not in one but in two near-by 
sites, respectively located at the cytosolic JM 
region (residues 676-689) and at a more distally 
located segment (residues 714-732) (76). The 676-
689 segment was proposed to be the site of 
interaction for apo-CaM, while both the 676-689 
and 714-732 segments contribute to the Ca2+-
dependent binding (76). 
In addition to the canonical signaling functions 
exerted by ErbB receptors when located at the 
plasma membrane and/or after internalization from 
intracellular vesicles, these receptors are known to 
translocate to the nucleus after ligand-induced 
activation where they appear to control 
transcriptional events relevant for cell proliferation 
and other functions (77-79). Although it is well 
established that ErbB4 is proteolytically processed 
before nuclear translocation and only the cytosolic 
segment moves to the nucleus, the full-length 
EGFR has been proposed to undergo nuclear 
translocation by a not fully understood mechanism 
(80). This has opened a strong controversy because 
it was argued that the experimental evidence for its 
location in the nucleoplasm was not as strong as 
suggested (81). Most significantly, it is not clear 
how the full-length receptor harboring a 
hydrophobic transmembrane segment undergoes its 
passage through a nuclear pore. Because the 
endoplasmic reticulum and the nuclear membrane 
form a network this could result in the 
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misidentification of the compartment where the 
full-length receptor is indeed located. 
 
Targeting ErbB receptors in cancer 
 
Overexpression and/or the occurrence of truncated, 
site-mutated or segment-deleted hyperactive forms 
of EGFR and ErbB2 are common findings in many 
solid tumors in humans. These aberrant receptors 
significantly contribute to the oncogenic process 
and they have been studied in great detail (82-92). 
Additionally, oncogenic mutations are also found 
in a variety of proteins involved in the downstream 
signaling pathways of the ErbB receptors, as for 
example in those of the EGFR (93). 
Consequently, targeting overexpressed and/or 
aberrant hyperactive ErbB receptors in anaplastic 
cells could be a valid therapeutic approach against 
cancer. In this context, a variety of EGFR and 
ErbB2 inhibitors have been developed, some of 
which are under test in clinical trials or are 
currently used in the clinic. These agents fall into 
two major categories: tyrosine kinase antagonists 
and inhibitory antibodies. Small molecules that 
bind to the tyrosine kinase domain of the receptor 
inhibiting its intrinsic tyrosine kinase activity form 
the first group. These compounds may specifically 
act on a single type of ErbB receptor, may have 
dual action inhibiting two receptor types (for 
example EGFR and ErbB2), or may have anti-pan-
ErbB activity (94-100). Some of these compounds 
were identified from a database of traditional 
medicinal plants by virtually screening their 
potential inhibitory action on the tyrosine kinase 
activity of the EGFR (101). The second category of 
inhibitors includes chimeric, humanized or human 
monoclonal antibodies targeting the EGFR or 
ErbB2 (98, 102-107). Emerging techniques such as 
those using the minimum antigen-recognizing 
segment of the immunoglobulin against the 
receptor and/or fusing cytotoxic effector molecules 
- for example a toxin or an RNase - to a small 
segment of the anti-ErbB immunoglobulin have 
been developed to increase the efficacy of these 
immunodrugs (104, 108, 109). 
As is common with other chemotherapeutic 
compounds, the use of anti-ErbB receptor agents 
may have important drawbacks that diminish or 
totally prevent their efficacy. This could be due to 
the occurrence of primary resistance of the tumor 
cells because of the expression of mutant receptors 
insensitive to the drug; or the establishment of 
acquired resistance induced by a variety of 
mechanisms including the appearance of secondary 
mutations (110-113). Another important problem 
when dispensing these antibodies to patients is the 
appearance of systemic or organ-selective toxic 
effects, for example cardiotoxicity (114, 115). 
In addition to anti-ErbB receptor drugs 
targeting either the tyrosine kinase domain or the 
extracellular region of the receptor preventing 
ligand binding, activation, internalization, 
trafficking and/or signaling, there are other 
important functional sites in these receptors that 
could be targeted to inhibit their activity. An 
emerging target site of interest could be the CaM-
BD located at the cytosolic JM region of the 
receptor, as we will describe in the next section. 
 
Targeting the calmodulin-binding domain of the 
EGFR 
 
The proximal segment of the cytosolic JM region 
of the human EGFR (residues 645-663, coded by 
exon 17), comprising the CaM-BD (residues 645-
660) plays an important role in the functionality of 
the receptor, as its impairment results in the loss of 
most of its intrinsic tyrosine kinase activity without 
affecting ligand binding. This has been 
demonstrated either by deletion of this region (69, 
116); substitution of critical positively-charged 
amino acids using site-directed mutagenesis, as for 
example replacing several arginine/lysine by 
neutral asparagine or alanine (73, 116, 117); or 
replacing the JM (amino acids 650-680) with an 
unstructured (GGS)10 sequence (118). The R646 
and R647 residues in the proximal part of the 
cytosolic JM region plus additional residues in the 
distal JM segment (residues 664-682, coded by 
exon 18) appear to be most relevant to preserve 
EGFR activity (117). The importance of the JM 
region for the activity of the receptor appears to 
rest in its participation in helping to form an 
asymmetric dimer involving two apposed tyrosine 
kinase domains stabilizing the dimer upon ligand 
binding (117, 119). A mutation (V665M) in the 
distal part of the cytosolic JM region has been 
shown to constitutively activate the EGFR in 
human non-small cell lung cancer (NSCLC) (117). 
However, two small-scale screenings for potential 
mutations in the JM of the four ErbB receptors 
gave negative results in a series of 200 human 
NSCLC samples (120) and 86/89 human astrocytic 
glioma samples (87, 121), suggesting that perhaps 
mutations in the JM segment are rare as it is 
required for receptor activity. 
Targeting the cytosolic JM region of the 
EGFR, where the CaM-BD is located, could be an 
efficient new strategy to inhibit the overexpressed 
and/or constitutively active mutant receptor present 
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in many tumor cells. Some exciting results have 
recently been obtained in this context. Thus, it has 
been demonstrated that a peptide corresponding to 
the proximal part of the cytosolic JM region 
(residues 645-662), tagged with a segment 
corresponding to the transactivation of 
transcription (Tat) sequence of HIV to allow its 
entry in the cell, induces non-apoptotic cell death 
after several hours of treatment, and caspase-3-
mediated apoptosis after longer exposure in a 
variety of tumor cells expressing EGFR, but 
having reduced action on non-tumor cells and 
tumor cells not expressing EGFR (122). This 
peptide also decreases tumor growth in vivo, and 
increases the survival rate of experimental animals 
implanted with the tumor cells (122). The 
mechanism of action of the peptide appears 
mediated by its binds to the EGFR preventing 
receptor dimerization and favoring its down-
regulation (122). 
A peptide corresponding to the sequence 
R651-L658 of the EGFR in which threonine 654 
has been substituted by a cysteine (RKRCLRRL, 
abbreviated T654C) (see Figure 1b) has been 
shown to inhibit PKC in an irreversible fashion 
because forms a disulfide bridge with a cysteine 
located in the catalytic site of the kinase (123). 
PKC is known to phosphorylate the EGFR at T654 
(124), and to test whether this peptide was able as 
well to inhibit ligand-dependent activation of the 
EGFR in intact cells it was tagged with the 
membrane-permeable carrier sequence 
AAVALLPAVLLALAP (see Figure 1b). This 
sequence comprises the hydrophobic (h)-region of 
the signal sequence of the Kaposi fibroblast growth 
factor and is unlikely to produce by itself toxic 
effects, as it is a physiological signal peptide 
facilitating protein secretion (125). Moreover, this 
specific carrier sequence has been previously used 
to introduce several effector peptides inside living 
cells in order to disrupt the functionality of a 
variety of signaling pathways (126, 127). 
We have demonstrated in murine EGFR-T17 
fibroblasts overexpressing the EGFR that the 
T654C peptide tagged with the cell-permeable 
sequence inhibits both the ligand-dependent 
phosphorylation (activation) of the EGFR (see 
Figure 1c), and cell proliferation as determined by 
[methyl-3H]thymidine incorporation into DNA (see 
Figure 1d), in contrast to the short T654C peptide 
lacking the carrier sequence and therefore unable 
to enter into the cells, at least with significant 
efficiency. The treatment of cells with the long 
T654C cell-permeable peptide eventually leads to 
cell death (Ruano and Villalobo, unpublished). The 
inhibitory effect of this peptide was also 
demonstrated in human epidermoid carcinoma 
A431 cells that also overexpress the EGFR (Ruano 
and Villalobo, unpublished). It is likely that the 
overexpression of the EGFR might facilitate the 
drastic inhibitory effects observed in these cells. 
The long T654C cell-permeable peptide might 
have a complex mechanism of action since it is an 
inhibitor of PKC (123), and it has not been tested if 
the cysteine prevents CaM binding. Nevertheless, 
our results are in agreement with those recently 
published using a distinct, though overlapping, 
peptide that binds to the EGFR preventing 
dimerization (122). Because of their related 
sequences, it is likely that both peptides have 
EGFR-interacting capacity. 
This demonstrates that peptides based on the 
CaM-BD of the EGFR could be potential 
therapeutic agents against tumors expressing this 
receptor. Similarly, it could be important to 
explore in future studies the potential inhibitory 
action of cell-permeable peptides corresponding to 
the two CaM-BDs of ErbB2 in tumor cells 
expressing this receptor, as for example and most 
significant in some subtypes of human breast 
cancer. 
Interestingly, the proposed NLS of the EGFR 
(128) overlaps with its CaM-BD (77) (see Figure 
1a). This underscores the potential implication of 
CaM in the regulation of the nuclear translocation 
of the EGFR, even if only the cytosolic portion but 
not the full-length receptor moves to the nucleus. 
Nuclear EGFR associates to the catalytic subunit 
of DNA-PK inducing DNA repair. Mutation or 
deletion of the overlapping CaM-BD/NLS, 
however, prevents the nuclear localization of the 
EGFR and its association to DNA-PK, thus 
dampening the activity of this enzyme and 
subsequently reducing the DNA repairing activity 
(129). This may decrease the efficiency to the 
treatment of patients undergoing chemotherapy or 
ionizing radiation, highlighting the potential 
usefulness of targeting this region of the EGFR to 
additionally reduce the occurrence of resistance to 
these treatments in cancer patients. 
 
Grb7 AND CALMODULIN 
 
Our laboratory has also described the presence of a 
CaM-BD in the proximal region of the PH domain 
of human Grb7 comprising the sequence 
243RKLWKRFFCFLRRS256 that is predicted to 
form a basic amphipathic α-helix (see Figure 2a) 
(41). Sequence homology analysis shows that the 
CaM-BD of human, rat and mouse Grb7 are  
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Figure. 1. Inhibitory effects of a modified cell-
permeable EGFR peptide. a) Schematic representation 
of the EGFR structure showing the extracellular region 
containing two cysteine-rich domains (CRD); the 
transmembrane segment (TM); and the intracellular 
region comprising the cytosolic juxtamembrane 
segment (JM), the tyrosine kinase domain (TK), and the 
C-terminal tail with auto-phosphorylatable tyrosine 
residues (Y). The calmodulin-binding domain (CaM-
BD), which overlaps the nuclear localization sequence 
(NLS), located in the proximal region of the cytosolic 
JM segment is indicated. The PKC-phosphorylatable 
residue T654 is highlighted. b) Amino acid sequences of 
the short and long (cell-permeable) T654C peptides. 
The N-terminal hydrophobic tag (plain font) and the 
substituted residue C654 are highlighted. c) The plot 
presents the mean ± range (n = 2) ligand-dependent 
phosphorylation of the EGFR in the presence of 
increasing concentrations of the short (circles) and long 
cell-permeable (triangles) peptides added to EGFR-T17 
fibroblasts. d) The plot presents the mean ± SEM (n = 4) 
incorporation of [methyl-3H]thymidine into DNA of 
EGFR-T17 fibroblasts in the absence (open symbols) 
and presence (filled symbols) of serum at increasing 
concentrations of the short (circles) and long cell-
permeable (triangles) peptides (Ruano and Villalobo, 
unpublished). 
 
identical, and that this region is highly conserved in 
Grb10 and Grb14 (23, 41). The truncated splice 
variant Grb7V lacking the C-terminal SH2 domain 
and expressed in certain adenocarcinomas (29) also 
maintains intact its CaM-BD (23, 41). 
We have demonstrated that CaM binds to Grb7 
and Grb7V in a Ca2+-dependent manner in vitro 
and in living cells, and that the deletion mutants 
Grb7∆ and Grb7V∆ lacking the sequence 
corresponding to the proposed CaM-BD result in 
the near full loss of their capacity to bind CaM 
(41). Grb7∆ and Grb7V∆ have less ability to bind 
to membranes although they retain in part their 
capacity to bind to some phosphoinositides (41). 
Moreover, the CaM antagonist W-7 - but not the 
CaMK-II inhibitor KN93 - prevents the 
translocation of Grb7 from the membrane to the 
cytosol upon activation of ErbB2 induced by 
heregulin ß1 in live cells, and a cell-permeable 
CaM sequestering peptide corresponding to the 
CaM-BD of MLCK decreases the association of 
Grb7 to cell membranes (41). Also, we have 
demonstrated that wild type Grb7 is translocated to 
the nucleus and that W-7 enhances this process, 
while Grb7∆ lacks this capacity (130). As the NLS 
and CaM-BD of Grb7 share superimposed 
sequences (see Figure 2a), our results suggest that 
CaM binding to Grb7 could occlude its NLS 
preventing in this manner the translocation of the 
protein to the nucleus and downstream signaling 
events occurring at this location (130). 
 
Targeting Grb7 in cancer 
 
Grb7 has been proposed to be a promising new 
target for anti-cancer therapy, as disrupting its 
functionality could inhibit the migratory capacity 
of tumor cells, their invasiveness and metastatic 
potential, and/or cell proliferation. As an example, 
it has been proposed that targeting the Grb7/ERK 
pathway and the downstream transcription factor 
FOXM1 could be a useful strategy to inhibit the 
growth, cell migratory capacity and invasiveness of 
ovarian tumor cells, as demonstrated in vitro and in 
vivo (131). 
The SH2 domain of Grb7 has been suggested 
as a key target to inhibit this adaptor protein, most 
prominently using mimetic peptides (132). The 
cyclic structure of a small synthetic non-
phosphorylated peptide containing an YXN motif, 
where X represents any amino acid, was shown to 
bind to the SH2 domain of Grb7 disrupting the 
interaction between Grb7 and ErbB receptors 
(133), and Grb7 and FAK (134). The peptide 
denoted G7-18NATE, with the sequence 
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WFEGYDNTFPC, that cyclizes forming a 
thioether bond, inhibits the proliferation of a series 
of human breast cancer cells expressing Grb7 when 
tagged with a cell-permeable carrier sequence (37), 
and attenuates as well cell migration and the 
development of peritoneal metastasis from a 
primary pancreatic tumor in a mouse model (134). 
Furthermore, the G7-18NATE peptide presents a 
synergistic effect with other classical 
chemotherapeutic agents, such as the DNA-
intercalating agent Doxorubicin, and the 
monoclonal antibody against ErbB2 denoted 
Trastuzumab (Herceptin) (37). 
Moreover, a series of eleven benzopyrazine 
derivatives (135) and nine phenylbenzamine 
derivatives (136) targeting the SH2 domain of 
Grb7 have also been tested as potential antagonists 
of this adaptor protein. The leading compounds in 
the two series inhibited in culture the viability of a 
human breast cancer cell line overexpressing Grb7 
(135, 136). These compounds were most effective 
at concentrations in the medium µmolar range 
(135, 136). Nevertheless, their efficacy, if any, 
against tumors in vivo remains to be tested. 
 
 
 
Figure. 2. Deletion of the CaM-BD of Grb7 decreases 
cell proliferation. a) Schematic representation of the 
Grb7 structure showing the PR, RA, PH, BPS and SH2 
domains and highlighting the central GM region (see 
text for details). The calmodulin-binding domain (CaM-
BD), overlapping the nuclear localization sequence 
(NLS), located in the proximal region of the PH domain 
is indicated. b) The plot shows the proliferation of non‐
transfected (NT) and stably transfected HEK-293 cells 
expressing Grb7 or Grb7Δ growing in the presence of 
serum and monitored in an xCELLigence RTCA system 
(García-Palmero and Villalobo, unpublished). 
Targeting the calmodulin-binding domain of 
Grb7 
 
To the best of our knowledge there is no 
information available on inhibitory compounds 
specifically targeting the CaM-BD of Grb7. 
However, this region of the protein could be a 
potential target for therapeutic intervention. This is 
based on interesting inhibitory effects observed in 
cells expressing the deletion mutant EYFP-Grb7∆ 
that lacks the CaM-BD, as compared to cells 
expressing EYFP-Grb7 (wild type) or EYFP alone. 
Thus, we have shown that rat glioma C6 cells 
expressing the mutant protein presented lower 
proliferation rate and diminished migratory 
capacity than the control cells (38). As an 
additional example, the inhibitory action of Grb7∆ 
on the proliferation of HEK-293 cells, as compared 
to wild type Grb7 or non-transfected cells is 
documented in Figure 2b. Although overexpression 
of Grb7 in tumors induces cell growth, the 
observed inhibitory effect of wild type Grb7 as 
compared to non-expressing cells (Figure 2b and 
Ref. 38), suggests that Grb7 may have a biphasic 
action when controlling cell proliferation. 
Expression of Grb7∆ also inhibits the migration of 
HEK-293 cells as compared to control cells 
(García-Palmero and Villalobo, unpublished 
results). Most relevant, these inhibitory effects 
were also observed in vivo measuring the growth of 
brain tumors derived from implanted C6 cells 
expressing the wild type and mutant proteins as 
determined by MRI (38). 
Conditioned media from cells expressing 
Grb7∆ or Grb7V∆ also present strong anti-
angiogenic activity, as compared to media from 
cells expressing their respective wild type 
counterparts, when tested on human vascular 
endothelial cells forming tubular structures in an in 
vitro assay system (41). The anti-angiogenic effect 
of Grb7∆ was also corroborated in vivo, as tumors 
derived from glioma C6 cells stably expressing the 
chimera EYFP-Grb7∆ and stereotaxically 
implanted in rat brain presented lower vascular 
performance and were less angiogenic that tumors 
derived from C6 cells stably expressing EYFP-
Grb7 or EYFP alone, as determined by MRI 
perfusion techniques (38). This opens the 
possibility that targeting the CaM-BD of Grb7 with 
selective cell-permeable peptides or other 
compounds in tumors naturally expressing this 
adaptor protein could be an additional strategy to 
inhibit tumor-associated angiogenesis and tumor 
growth. 
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FUTURE PERSPECTIVES 
 
Many studies mostly performed in vitro point to a 
potential benefit of treating cancers with CaM 
antagonists. However, the therapeutic benefit of 
this strategy in patients has yet to be demonstrated 
because of the noxious side effects expected, even 
using sub-optimal doses. An alternative strategy 
that should be explored is targeting the site(s) of 
action of CaM in specific CaM-dependent systems 
that are upregulated and/or overexpressed in tumor 
cells, as we have proposed in this review with the 
CaM-BD of ErbB receptors and Grb7. 
Combinatory therapy targeting several systems at 
once could be a way to minimize the appearance of 
resistance to the drugs. Efforts are needed to 
discover specific biomarkers for the selective 
delivery of the intended drugs to the tumor, 
particularly targeting the tumor stem-cells, 
avoiding as much as possible the normal tissues. 
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